Back to top
more

Editas Medicine (EDIT)

(Real Time Quote from BATS)

$10.73 USD

10.73
144,508

+0.12 (1.13%)

Updated Nov 30, 2023 10:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.96%
2Buy17.61%
3Hold8.96%
4Sell4.80%
5Strong Sell2.32%
S&P50010.64%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for EDIT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Editas Medicine, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Assets          
Cash & Equivalents 344 500 402 457 369
Receivables 5 0 6 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 7 7 11 6 6
Total Current Assets 357 507 419 464 375
Net Property & Equipment 16 17 14 11 40
Investments & Advances 93 120 110 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 5 7 5 5 5
Total Assets 514 677 573 509 420
Liabilities & Shareholders Equity 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Notes Payable 0 0 0 0 0
Accounts Payable 10 5 6 6 5
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 31 20 24 22 13
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 8 11 21 26 18
Total Current Liabilities 60 47 58 60 36
Mortgages 0 0 0 0 0
Deferred Taxes/Income 61 61 74 163 116
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 32
Other Non-Current Liabilities 0 0 28 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 154 124 179 246 184
Shareholders Equity 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,442 1,412 1,059 812 652
Retained Earnings -1,078 -858 -665 -549 -416
Other Equity -4 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 361 554 394 262 236
Total Liabilities & Shareholder's Equity 514 677 573 509 420
Total Common Equity 361 554 394 262 236
Shares Outstanding 68.70 68.40 62.60 51.30 47.80
Book Value Per Share 5.25 8.09 6.29 5.12 4.94

Fiscal Year End for Editas Medicine, Inc falls in the month of December.

All items in Millions except Per Share data.

9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Assets          
Cash & Equivalents 350 432 318 344 420
Receivables 2 2 0 5 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 7 7 6 7 7
Total Current Assets 359 441 324 357 427
Net Property & Equipment 12 13 13 16 15
Investments & Advances 97 48 83 93 59
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 6 5 7 5 8
Total Assets 505 542 464 514 531
Liabilities & Shareholders Equity 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Notes Payable 0 0 0 0 0
Accounts Payable 10 8 9 10 7
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 30 28 32 31 19
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 8 8 8 8 4
Total Current Liabilities 59 55 57 60 42
Mortgages 0 0 0 0 0
Deferred Taxes/Income 61 61 61 61 65
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 144 142 147 154 116
Shareholders Equity 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,574 1,570 1,447 1,442 1,436
Retained Earnings -1,212 -1,167 -1,127 -1,078 -1,017
Other Equity -1 -2 -2 -4 -4
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 360 400 317 361 415
Total Liabilities & Shareholder's Equity 505 542 464 514 531
Total Common Equity 360 400 317 361 415
Shares Outstanding 81.60 81.60 69.00 68.70 68.70
Book Value Per Share 4.42 4.90 4.60 5.25 6.04